Kala Pharmaceuticals Inc. [NASDAQ: KALA] closed the trading session at $0.33 on 08/11/22. The day’s price range saw the stock hit a low of $0.29, while the highest price level was $0.43. The company report on August 11, 2022 that Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
— Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 —- Received $60M Upfront Payment from Sale of EYSUVIS® and INVELTYS® to Alcon Inc. and Significantly Reduced Operating Expenses, Extending Cash Runway into 2Q 2024 — — Conference Call and Webcast at 8:00 a.m. ET –.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
The stocks have a year to date performance of -72.89 percent and weekly performance of -2.70 percent. The stock has been moved at -58.48 percent over the last six months. The stock has performed -2.29 percent around the most recent 30 days and changed -48.77 percent over the most recent 3-months.
If compared to the average trading volume of 1.73M shares, KALA reached to a volume of 8220907 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Kala Pharmaceuticals Inc. [KALA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KALA shares is $2.69 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KALA stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Kala Pharmaceuticals Inc. shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on March 30, 2022. The new note on the price target was released on August 06, 2021, representing the official price target for Kala Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $10, while Jefferies analysts kept a Hold rating on KALA stock.
The Average True Range (ATR) for Kala Pharmaceuticals Inc. is set at 0.04, with the Price to Sales ratio for KALA stock in the period of the last 12 months amounting to 2.54.
KALA stock trade performance evaluation
Kala Pharmaceuticals Inc. [KALA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.70. With this latest performance, KALA shares dropped by -2.29% in over the last four-week period, additionally sinking by -58.48% over the last 6 months – not to mention a drop of -89.69% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KALA stock in for the last two-week period is set at 46.14, with the RSI for the last a single of trading hit 47.54, and the three-weeks RSI is set at 43.57 for Kala Pharmaceuticals Inc. [KALA]. The present Moving Average for the last 50 days of trading for this stock 0.3457, while it was recorded at 0.3381 for the last single week of trading, and 0.9724 for the last 200 days.
Kala Pharmaceuticals Inc. [KALA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Kala Pharmaceuticals Inc. [KALA] shares currently have an operating margin of -973.60 and a Gross Margin at +63.55. Kala Pharmaceuticals Inc.’s Net Margin is presently recorded at -1268.73.
Return on Equity for this stock declined to -244.19, with Return on Assets sitting at -79.00.
Kala Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 3.00.
Earnings per share (EPS) analysis for Kala Pharmaceuticals Inc. [KALA] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for KALA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Kala Pharmaceuticals Inc. go to 40.90%.
Kala Pharmaceuticals Inc. [KALA]: Insider Ownership positions
There are presently around $8 million, or 31.00% of KALA stock, in the hands of institutional investors. The top three institutional holders of KALA stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 10,874,613, which is approximately 0% of the company’s market cap and around 1.20% of the total institutional ownership; BLACKROCK INC., holding 3,127,650 shares of the stock with an approximate value of $1.03 million in KALA stocks shares; and VANGUARD GROUP INC, currently with $0.55 million in KALA stock with ownership of nearly -22.151% of the company’s market capitalization.
Positions in Kala Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 24 institutional holders increased their position in Kala Pharmaceuticals Inc. [NASDAQ:KALA] by around 1,631,902 shares. Additionally, 58 investors decreased positions by around 3,435,272 shares, while 22 investors held positions by with 18,169,456 shares. The mentioned changes placed institutional holdings at 23,236,630 shares, according to the latest SEC report filing. KALA stock had 13 new institutional investments in for a total of 986,723 shares, while 17 institutional investors sold positions of 1,001,713 shares during the same period.